DeepMed Research

Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer

Phase 2

Conditions: Locally Advanced Pancreatic Cancer

Interventions: Drug: Nab-paclitaxel and S-1

First Posted Date: 2019-01-24

Last Posted Date: 2019-01-25

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT03815461

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

HFSRT With Concurrent TMZ for Large BMs

Phase 3

Conditions: Brain Metastases
Radiotherapy
Chemotherapy

Interventions: Drug: Temozolomide
Radiation: hypofractionated radiotherapy

First Posted Date: 2018-12-19

Last Posted Date: 2019-07-23

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 224

Registration Number: NCT03778541

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Apatinib
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2018-11-08

Last Posted Date: 2018-11-08

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 29

Registration Number: NCT03735082

Locations: 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

Phase 1

Conditions: Tumor, Solid
Lymphoma

Interventions: Drug: GR1405 injection

First Posted Date: 2018-11-06

Last Posted Date: 2018-11-06

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT03731390

Locations: 🇨🇳
Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Phase 3

Recruiting

Conditions: Esophageal Cancer

Interventions: Radiation: Involved field irradiation
Radiation: Elective field irradiation
Drug: Paclitaxel
Drug: Platinum
Drug: PEG-rhG-CSF

First Posted Date: 2018-11-06

Last Posted Date: 2018-12-12

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 300

Registration Number: NCT03731442

Locations: 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, Beijing, China

Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

Phase 1

Conditions: Recurrent Nasopharyngeal Carcinoma
Metastatic Nasopharyngeal Carcinoma

Interventions: Drug: Anlotinib plus gemcitabine/cisplatin

First Posted Date: 2018-08-21

Last Posted Date: 2018-09-18

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT03639467

Locations: 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Phase 1

Conditions: NSCLC
Adenocarcinoma
Squamous Cell Carcinoma

Interventions: Drug: Anlotinib combined with pemetrexed and carboplatin, phase I
Drug: Anlotinib combined with paclitaxel and carboplatin, phase I
Drug: Anlotinib combined with pemetrexed and carboplatin, phase II
Drug: Anlotinib combined with paclitaxel and carboplatin, phase II

First Posted Date: 2018-08-17

Last Posted Date: 2018-08-17

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT03636685

Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma

Phase 2

Conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

First Posted Date: 2018-08-15

Last Posted Date: 2018-08-15

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 32

Registration Number: NCT03630731

Locations: 🇨🇳
Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, Beijing, China

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: SHR-1210
Drug: Apatinib
Drug: Paclitaxel liposome
Drug: Irinotecan Injection
Drug: Nedaplatin

First Posted Date: 2018-07-27

Last Posted Date: 2020-02-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 45

Registration Number: NCT03603756

Locations: 🇨🇳
Jing Huang, Beijing, China

Randomized Trial of Accelerated Partial Breast Irradiation

Not Applicable

Completed

Conditions: Breast Neoplasms
Neoplasm Recurrence, Local

Interventions: Radiation: WBI
Radiation: APBI

First Posted Date: 2018-07-11

Last Posted Date: 2020-03-25

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 140

Registration Number: NCT03583619

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy